Resources from the same session
2MO - First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): clinical outcomes and biomarker analyses from CheckMate 592
Presenter: Michael Schenker
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
3MO - Comprehensive biomarkers (BMs) analysis to predict efficacy of PD1/L1 immune checkpoint inhibitors (ICIs) in combination with chemotherapy: a subgroup analysis of the Precision Immuno-Oncology for advanced Non-Small CEll Lung CancER (PIONeeR) trial
Presenter: Fabrice Barlesi
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
LBA3 - Compartmental Radioimmunotherapy (cRIT) 131I-OMBURTAMAB in Patients with Neuroblastoma (NB) Central Nervous System (CNS) and/or Leptomeningeal (LM) Metastases: Updated Results from Pivotal Trial 101
Presenter: Ellen Basu
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
62MO - Naxitamab Pivotal Clinical Trial Planned Interim Analysis of PFS and OS in Patients with Relapsed or Refractory High-risk Neuroblastoma
Presenter: Jaume Mora
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
LBA1 - Tissue-agnostic response predictor for immune checkpoint inhibitor therapy based on MKI67, FOXC1 and PDL1 expression
Presenter: Partha Ray
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
200MO - Anti-IL-8 BMS-986253 + nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with advanced cancer: update of initial phase 1 results
Presenter: Matteo Simonelli
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant
Presenter: Anna Di Giacomo
Session: Mini Oral session 2
Resources:
Slides
Webcast
Invited Discussant
Presenter: Samra Turajlic
Session: Mini Oral session 2
Resources:
Slides
Webcast